title: Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
abstract: The development of multitargeted tyrosine kinase inhibitors has provided significant advances in the treatment of renal cell carcinoma. This case describes initial therapy for managing renal cell cancer with the administration of sorafenib, a multitargeted tyrosine kinase inhibitor. We report the development of localized palmar-plantar epidermal hyperplasia, a rare but significant cutaneous adverse event from sorafenib therapy. Mild-to-moderate dermatologic toxicity from sorafenib has been well described in the literature. We also review the current knowledge and the proposed hypothesis for the development of cutaneous events related to tyrosine kinase inhibitors. This particular case represents a unique form of dermatologic toxicity to sorafenib that has not previously been described in the literature.
authors.affiliation: Department of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina 29425, USA. beldner@musc.edu
authors.forename: Matthew
authors.initials: M
authors.lastname: Beldner
authors.forename: Michael
authors.initials: M
authors.lastname: Jacobson
authors.forename: Gene E
authors.initials: GE
authors.lastname: Burges
authors.forename: Deborah
authors.initials: D
authors.lastname: Dewaay
authors.forename: John C
authors.initials: JC
authors.lastname: Maize
authors.forename: Uzair B
authors.initials: UB
authors.lastname: Chaudhary
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology; D004890:Erythema / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D012871:Skin Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D040262:Receptors, Vascular Endothelial Growth Factor